

Ping Chi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2470990/publications.pdf>

Version: 2024-02-01

67
papers

6,781
citations

159585
30
h-index

114465
63
g-index

68
all docs

68
docs citations

68
times ranked

12587
citing authors

#	ARTICLE	IF	CITATIONS
1	OncoKB: A Precision Oncology Knowledge Base. <i>JCO Precision Oncology</i> , 2017, 2017, 1-16.	3.0	1,266
2	Organoid Cultures Derived from Patients with Advanced Prostate Cancer. <i>Cell</i> , 2014, 159, 176-187.	28.9	1,184
3	PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. <i>Nature Genetics</i> , 2014, 46, 1227-1232.	21.4	472
4	Histone H3K36 mutations promote sarcomagenesis through altered histone methylation landscape. <i>Science</i> , 2016, 352, 844-849.	12.6	327
5	Synapsin dispersion and reclustering during synaptic activity. <i>Nature Neuroscience</i> , 2001, 4, 1187-1193.	14.8	317
6	ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. <i>Nature</i> , 2010, 467, 849-853.	27.8	279
7	Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib. <i>JAMA Oncology</i> , 2016, 2, 937.	7.1	241
8	Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma. <i>Nature Genetics</i> , 2016, 48, 675-680.	21.4	236
9	Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 923-934.	10.7	224
10	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. <i>Cell</i> , 2022, 185, 563-575.e11.	28.9	223
11	Alternative transcription initiation leads to expression of a novel ALK isoform in cancer. <i>Nature</i> , 2015, 526, 453-457.	27.8	191
12	Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab. <i>JAMA Oncology</i> , 2020, 6, 402.	7.1	125
13	The management of metastatic GIST: current standard and investigational therapeutics. <i>Journal of Hematology and Oncology</i> , 2021, 14, 2.	17.0	107
14	Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab. <i>Clinical Cancer Research</i> , 2017, 23, 2972-2980.	7.0	106
15	Combined Inhibition of MAP Kinase and KIT Signaling Synergistically Destabilizes ETV1 and Suppresses GIST Tumor Growth. <i>Cancer Discovery</i> , 2015, 5, 304-315.	9.4	102
16	Clinical and Morphologic Characteristics of MEK Inhibitor-Associated Retinopathy. <i>Ophthalmology</i> , 2017, 124, 1788-1798.	5.2	95
17	Melanoma models for the next generation of therapies. <i>Cancer Cell</i> , 2021, 39, 610-631.	16.8	90
18	Spindle Cell Tumors With RET Gene Fusions Exhibit a Morphologic Spectrum Akin to Tumors With NTRK Gene Fusions. <i>American Journal of Surgical Pathology</i> , 2019, 43, 1384-1391.	3.7	78

#	ARTICLE	IF	CITATIONS
19	GNA11 Q209L Mouse Model Reveals RasGRP3 as an Essential Signaling Node in Uveal Melanoma. <i>Cell Reports</i> , 2018, 22, 2455-2468.	6.4	75
20	Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets. <i>Science</i> , 2022, 376, .	12.6	75
21	Co-targeting of BAX and BCL-XL proteins broadly overcomes resistance to apoptosis in cancer. <i>Nature Communications</i> , 2022, 13, 1199.	12.8	66
22	Identification of Cancer Drivers at CTCF Insulators in 1,962 Whole Genomes. <i>Cell Systems</i> , 2019, 8, 446-455.e8.	6.2	65
23	Expanding the Molecular Characterization of Thoracic Inflammatory Myofibroblastic Tumors beyond ALK Gene Rearrangements. <i>Journal of Thoracic Oncology</i> , 2019, 14, 825-834.	1.1	62
24	Aberrant Activation of a Gastrointestinal Transcriptional Circuit in Prostate Cancer Mediates Castration Resistance. <i>Cancer Cell</i> , 2017, 32, 792-806.e7.	16.8	61
25	Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib. <i>Journal of Clinical Oncology</i> , 2020, 38, 3294-3303.	1.6	61
26	SWI/SNF Complex Mutations Promote Thyroid Tumor Progression and Insensitivity to Redifferentiation Therapies. <i>Cancer Discovery</i> , 2021, 11, 1158-1175.	9.4	57
27	FOXF1 Defines the Core-Regulatory Circuitry in Gastrointestinal Stromal Tumor. <i>Cancer Discovery</i> , 2018, 8, 234-251.	9.4	49
28	Phase 2 study of the CDK4 inhibitor abemaciclib in dedifferentiated liposarcoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 11004-11004.	1.6	44
29	Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers. <i>Journal of Hematology and Oncology</i> , 2018, 11, 78.	17.0	39
30	A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor. <i>Investigational New Drugs</i> , 2019, 37, 282-290.	2.6	32
31	COP1/DET1/ETS axis regulates ERK transcriptome and sensitivity to MAPK inhibitors. <i>Journal of Clinical Investigation</i> , 2018, 128, 1442-1457.	8.2	30
32	Combined Inhibition of G1±q and MEK Enhances Therapeutic Efficacy in Uveal Melanoma. <i>Clinical Cancer Research</i> , 2021, 27, 1476-1490.	7.0	29
33	ERG orchestrates chromatin interactions to drive prostate cell fate reprogramming. <i>Journal of Clinical Investigation</i> , 2020, 130, 5924-5941.	8.2	29
34	A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue Sarcomas. <i>Oncologist</i> , 2015, 20, 1245-1246.	3.7	25
35	A Clinicopathologic Study of Head and Neck Malignant Peripheral Nerve Sheath Tumors. <i>Head and Neck Pathology</i> , 2018, 12, 151-159.	2.6	23
36	Direct evidence that the GPCR CysLTR2 mutant causative of uveal melanoma is constitutively active with highly biased signaling. <i>Journal of Biological Chemistry</i> , 2021, 296, 100163.	3.4	22

#	ARTICLE	IF	CITATIONS
37	A Phase Ib/II Randomized Study of RO4929097, a Gamma-Secretase or Notch Inhibitor with or without Vismodegib, a Hedgehog Inhibitor, in Advanced Sarcoma. <i>Clinical Cancer Research</i> , 2022, 28, 1586-1594.	7.0	20
38	Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single center. , 2022, 10, e004149.		20
39	Ripretinib inpatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour. <i>European Journal of Cancer</i> , 2021, 155, 236-244.	2.8	19
40	A Tmprss2-CreERT2 Knock-In Mouse Model for Cancer Genetic Studies on Prostate and Colon. <i>PLoS ONE</i> , 2016, 11, e0161084.	2.5	18
41	Clinical Outcome of Leiomyosarcomas With Somatic Alteration in Homologous Recombination Pathway Genes. <i>JCO Precision Oncology</i> , 2020, 4, 1350-1360.	3.0	18
42	A phase Ib/II study of MEK162 (binimetinib [BINI]) in combination with imatinib in patients with advanced gastrointestinal stromal tumor (GIST).. <i>Journal of Clinical Oncology</i> , 2015, 33, 10507-10507.	1.6	16
43	Patient perspectives on ipilimumab across the melanoma treatment trajectory. <i>Supportive Care in Cancer</i> , 2017, 25, 2155-2167.	2.2	14
44	PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry. <i>Cancer Discovery</i> , 2022, 12, 2120-2139.	9.4	14
45	Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor. <i>Journal of Clinical Oncology</i> , 2022, 40, 997-1008.	1.6	13
46	ETV1-Positive Cells Give Rise to <i>BRAFV600E</i> -Mutant Gastrointestinal Stromal Tumors. <i>Cancer Research</i> , 2017, 77, 3758-3765.	0.9	12
47	HLA Genotyping in Synovial Sarcoma: Identifying HLA-A*02 and Its Association with Clinical Outcome. <i>Clinical Cancer Research</i> , 2020, 26, 5448-5455.	7.0	12
48	A phase II study of epacadostat and pembrolizumab in patients with advanced sarcoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 11049-11049.	1.6	12
49	Squamous cell carcinoma associated with chronic graft versus host disease-like/lichen planus-like lesion of the oral cavity in a patient managed for metastatic melanoma with a PD-1 inhibitor pembrolizumab. <i>Oral Oncology</i> , 2016, 63, e1-e3.	1.5	11
50	Gastrointestinal stromal tumors with <i>BRAF</i> gene fusions. A report of two cases showing low or absent <i>KIT</i> expression resulting in diagnostic pitfalls. <i>Genes Chromosomes and Cancer</i> , 2021, 60, 789-795.	2.8	11
51	A phase II study of MEK162 (binimetinib [BINI]) in combination with imatinib in patients with untreated advanced gastrointestinal stromal tumor (GIST).. <i>Journal of Clinical Oncology</i> , 2020, 38, 11508-11508.	1.6	10
52	Long-term Follow-up and Patterns of Response, Progression, and Hyperprogression in Patients after PD-1 Blockade in Advanced Sarcoma. <i>Clinical Cancer Research</i> , 2022, 28, 939-947.	7.0	10
53	A phase 1b study of avelumab plus DCC-3014, a potent and selective inhibitor of colony stimulating factor 1 receptor (CSF1R), in patients with advanced high-grade sarcoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 11549-11549.	1.6	7
54	DNA damage response pathway alterations and clinical outcome in leiomyosarcoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 11048-11048.	1.6	7

#	ARTICLE	IF	CITATIONS
55	A phase II study of talimogene laherparepvec (T-VEC) and pembrolizumab in patients with metastatic sarcoma.. Journal of Clinical Oncology, 2018, 36, 11516-11516.	1.6	6
56	Pilot study of NKTR214 and nivolumab in patients with sarcomas.. Journal of Clinical Oncology, 2019, 37, 11010-11010.	1.6	6
57	<i><sc>FGFR2</sc>::<sc>TACC2</sc></i> fusion as a novel <sc>KIT</sc>â€independent mechanism of targeted therapy failure in a multidrugâ€resistant gastrointestinal stromal tumor. Genes Chromosomes and Cancer, 2022, 61, 412-419.	2.8	4
58	The clinical impact of performing routine next generation sequencing (NGS) in gastrointestinal stromal tumors (GIST).. Journal of Clinical Oncology, 2017, 35, 11010-11010.	1.6	3
59	Mutation profile of drug resistant gastrointestinal stromal tumor (GIST) patients (pts) enrolled in the phase 1 study of DCC-2618.. Journal of Clinical Oncology, 2018, 36, 11511-11511.	1.6	3
60	Phase Ib Trial of the Combination of Imatinib and Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumors. Clinical Cancer Research, 2022, 28, 1507-1517.	7.0	3
61	Lowâ€grade endometrial stromal sarcomaâ€like tumors in male with <sc><i>JAZF1</i></sc> gene fusions. Genes Chromosomes and Cancer, 2022, 61, 63-70.	2.8	2
62	Association of immune-related adverse events (irAEs) with improved clinical outcome in sarcoma patients treated with immune checkpoint blockade (ICB).. Journal of Clinical Oncology, 2020, 38, 11510-11510.	1.6	1
63	Risk factors associated with ifosfamide (IFOS)-induced encephalopathy in patients (pts) with metastatic (Met) sarcoma (Sarc).. Journal of Clinical Oncology, 2017, 35, e22518-e22518.	1.6	1
64	DICER1-Associated Anaplastic Sarcoma of the Kidney With Coexisting Activating PDGFRA D842V Mutations and Response to Targeted Kinase Inhibitors in One Patient. JCO Precision Oncology, 2022, , .	3.0	1
65	A phase Ib study of BCGJ398 in combination with imatinib in patients with advanced gastrointestinal stromal tumor (GIST).. Journal of Clinical Oncology, 2017, 35, 11039-11039.	1.6	0
66	Sequenced circulating tumor (ct) DNA to detect the molecular landscape in advanced GIST.. Journal of Clinical Oncology, 2019, 37, 11036-11036.	1.6	0
67	HLA genotyping in synovial sarcoma: Identifying HLA-A*02 and its association with clinical outcome.. Journal of Clinical Oncology, 2020, 38, e23560-e23560.	1.6	0